Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
← catalyst calendarNCT05658497 · readout in 2,148 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
908estimated
Sites
8
Countries
Australia, Germany, Ireland +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-27 | actual | When the study began enrolling |
| Primary completion | 2032-07-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-06 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Drug: Diroximel Fumarate — also filed as VUMERITY, BIIB098
- Drug: Avonex — also filed as BG9418, interferon beta-1a
- Biological: Tysabri — also filed as Natalizumab, BG00002
- Drug: Dimethyl Fumarate — also filed as Tecfidera, DMF, BG00012
Primary outcome
what the primary-completion date above is the date OFNumber of Major Congenital Malformations (MCMs)
measured Up to 52 weeks postdelivery
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed